Reported positive (1)
- Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Meta-analysis · Moderate evidence · Apr 2024
Pembrolizumab
Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
2 published studies tagged to this agent1 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?
Human trial / meta-analysis — Includes human trial or meta-analysis evidence.
- 1 human · 0 animal · 0 lab · 1 review/other
- Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
- Studies disagree on the reported direction (conflict flagged).
- Findings conflict across studies
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedpembrolizumab
Educational only, not medical advice. OncoForge makes no claim that Pembrolizumab treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 2 recent studies; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Endometrial Carcinosarcoma12—1
- Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis Meta-analysisReported positive
- Endometrial carcinosarcoma ReviewMixed results
Advanced Endometrial Cancer11—1
Recurrent Endometrial Cancer11—1
Reported figures
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline0
Meta-analysis1
Systematic review0
Randomized trial0
Clinical trial0
Observational0
Case report0
Review1
Preclinical0
Other0
2 studies1 human1 review/other
Tracking 2 published studies of Pembrolizumab: 1 in humans, 1 reviews/other.
Reported direction across studies: 1 positive, 1 mixed.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Pembrolizumab works.
Cancers named in these studies
Conflicting evidence
Negative or mixed (1)
- Endometrial carcinosarcoma
Review · Limited evidence · Feb 2023
All studies
Meta-analysisTrialReported positiveModerate evidenceTier 4 · clinicaln = 2456
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Cancer treatment reviews · Apr 2024 · meta-analysis of randomized controlled trials (first-line ICI + platinum-based chemotherapy vs chemotherapy alone)
AtezolizumabAvelumabDurvalumabDostarlimabPembrolizumabadvanced endometrial cancerrecurrent endometrial cancerendometrial carcinosarcoma
This meta-analysis pooled five randomized trials (2456 patients) comparing addition of anti-PD-1 or anti-PD-L1 agents to standard platinum-based chemotherapy versus chemotherapy alone as first-line treatment for advanced or recurrent endometrial cancer. Adding immune checkpoint inhibitors improved progression-free survival overall and especially in tumors with deficient mismatch repair (dMMR); in mismatch repair–proficient (pMMR) tumors a statistically significant PFS benefit was reported only with anti-PD-1 agents, not anti-PD-L1 agents. The analysis reports PFS outcomes; the impact on overall survival remains to be clarified.
Reported effects: included patients 2456, n=2456 · pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 · +5 more
Studied with: carboplatin-paclitaxel chemotherapy.
Key findings
- Five randomized trials comprising 2456 patients (1308 received ICIs + chemotherapy and 1148 chemotherapy alone) were included.
- Addition of ICIs to chemotherapy improved PFS in the overall population (pooled HR, 0.63; 95% CI, 0.52–0.76; P < .001).
- In the dMMR subgroup the pooled PFS benefit was larger (pooled HR, 0.34; 95% CI, 0.27–0.44; P < .001).
- In dMMR tumors benefit was seen with both PD-L1 and PD-1 inhibitors (pooled HRs 0.39, 95% CI 0.28–0.55 and 0.34, 95% CI 0.27–0.44, respectively; both P < .001).
- In pMMR patients a statistically significant PFS benefit was observed only with anti-PD-1 agents (anti-PD-1: HR 0.64, 95% CI 0.46–0.90, P = .010) but not with anti-PD-L1 agents (anti-PD-L1: HR 0.87, 95% CI 0.73–1.03, P = .104).
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewMechanismMixed resultsLimited evidenceTier 4 · clinical
Endometrial carcinosarcoma
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Feb 2023
This review summarizes current knowledge on endometrial carcinosarcoma, an aggressive high-grade endometrial carcinoma with sarcomatous trans-differentiation that is often diagnosed at an advanced stage. It describes common molecular features (frequent p53 abnormalities; variable POLE/MSI-H) and current management: multimodal therapy with optimal surgery plus chemotherapy and radiotherapy, carboplatin/paclitaxel as first-line systemic therapy for recurrent/metastatic disease, and regulatory approvals for pembrolizumab plus lenvatinib in endometrial cancer generally. The authors note that carcinosarcoma patients were excluded from many immunotherapy trials and that emerging molecular insights may enable more personalized treatments in the future.
Reported effects: proportion_in_endometrioid_components 25% · proportion_in_non-endometrioid_components 3%
Studied with: carboplatin/paclitaxel doublet, pembrolizumab + lenvatinib, concomitant or sequential chemotherapy and radiotherapy, surgery plus chemotherapy and radiotherapy (multimodal).
Key findings
- Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation.
- Clinical presentation and diagnostic work-up are similar to endometrioid endometrial cancer, but carcinosarcoma is more frequently diagnosed at an advanced stage.
- Endometrial carcinosarcoma encompasses different histological subtypes depending on the carcinomatous and sarcomatous elements.
- The majority of endometrial carcinosarcomas are characterized by p53 abnormalities.
- The proportion of POLE and microsatellite instability-high (MSI-H) is related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.
- Non-metastatic disease management is multimodal with optimal surgery followed by concomitant or sequential chemotherapy and radiotherapy, even for early stages.
- Palliative chemotherapy is recommended for metastatic or recurrent disease, with carboplatin/paclitaxel doublet as the first-line regimen.
- Patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or combinations, although pembrolizumab and lenvatinib have FDA and EMA approvals in endometrial cancer after progression on chemotherapy (and single-agent immunotherapy in MSI-H cancers).
- Emerging molecular knowledge is opening promising therapeutic options for more personalized treatment.
Limitations: This article is a narrative review rather than primary clinical trial data.; Endometrial carcinosarcoma is a rare and heterogeneous disease, limiting generalizable high-quality evidence.; Patients with carcinosarcoma were excluded from most immunotherapy studies, resulting in limited direct trial evidence for these agents in this histotype.; The abstract does not present new quantitative clinical trial outcomes specific to carcinosarcoma..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
What changed recently
The latest additions to Pembrolizumab's evidence base, and anything that's been retracted.
Recently added- Endometrial carcinosarcoma Review · added Jun 2026
- Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis Meta-analysis · added Jun 2026
Cancers where Pembrolizumab reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Human evidence
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)
Evidence at a glance: Pembrolizumab by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Includes human trial or meta-analysis evidence.
Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies
Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Findings conflict across studies.
Includes human trial or meta-analysis evidence.
Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies
Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Based on a single study.
Includes human trial or meta-analysis evidence.
Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies
Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Based on a single study.
Trials studying Pembrolizumab
Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.